Nkcfo LLC Trims Stake in ADMA Biologics Inc (NASDAQ:ADMA)

Key Points

• Nkcfo LLC significantly reduced its holdings in ADMA Biologics by selling 14,497 shares, bringing its ownership down to 4,453 shares valued at $88,000.
• In the 4th quarter, other institutional investors like B Group Inc. and Raymond James acquired significant positions in ADMA Biologics, with B Group investing approximately $39 million.
• ADMA Biologics reported a quarterly earnings miss with an EPS of $0.14, falling short of the expected $0.16, but showed a 40.2% year-over-year revenue growth.

Nkcfo LLC lowered its stake in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 76.5% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,453 shares of the biotechnology company's stock after selling 14,497 shares during the period. Nkcfo LLC's holdings in ADMA Biologics were worth $88,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. LPL Financial LLC grew its stake in shares of ADMA Biologics by 84.7% in the 1st quarter. LPL Financial LLC now owns 110,253 shares of the biotechnology company's stock worth $2,187,000 after buying an additional 50,565 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of ADMA Biologics by 1.1% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 66,671 shares of the biotechnology company's stock worth $1,323,000 after buying an additional 711 shares during the last quarter. Skandinaviska Enskilda Banken AB publ purchased a new stake in shares of ADMA Biologics in the 1st quarter worth approximately $35,000. Cetera Investment Advisers grew its stake in shares of ADMA Biologics by 1.3% in the 1st quarter. Cetera Investment Advisers now owns 50,511 shares of the biotechnology company's stock worth $1,002,000 after buying an additional 670 shares during the last quarter. Finally, Avantax Advisory Services Inc. lifted its position in ADMA Biologics by 1.8% in the 1st quarter. Avantax Advisory Services Inc. now owns 108,327 shares of the biotechnology company's stock valued at $2,149,000 after acquiring an additional 1,954 shares in the last quarter. Hedge funds and other institutional investors own 75.68% of the company's stock.

ADMA Biologics Stock Performance

Shares of NASDAQ ADMA traded up $0.21 during midday trading on Thursday, hitting $18.80. 925,857 shares of the stock traded hands, compared to its average volume of 3,061,135. The firm has a 50-day moving average of $18.86 and a two-hundred day moving average of $18.72. The firm has a market capitalization of $4.49 billion, a P/E ratio of 22.13 and a beta of 0.43. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.36 and a current ratio of 6.58. ADMA Biologics Inc has a one year low of $10.21 and a one year high of $25.67.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.16 by ($0.02). The firm had revenue of $114.80 million for the quarter, compared to the consensus estimate of $116.40 million. ADMA Biologics had a net margin of 45.01% and a return on equity of 47.16%. ADMA Biologics's quarterly revenue was up 40.2% compared to the same quarter last year. During the same period in the previous year, the company earned $0.08 earnings per share. On average, equities analysts forecast that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on ADMA. Raymond James Financial upped their price objective on ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research report on Thursday, May 8th. Wall Street Zen cut ADMA Biologics from a "hold" rating to a "sell" rating in a research report on Friday, May 9th.

Insider Activity

In other news, Director Jerrold B. Grossman sold 10,000 shares of the company's stock in a transaction on Monday, June 9th. The stock was sold at an average price of $21.31, for a total value of $213,100.00. Following the completion of the sale, the director directly owned 478,194 shares in the company, valued at $10,190,314.14. This represents a 2.05% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Lawrence P. Guiheen sold 20,000 shares of the company's stock in a transaction on Monday, June 9th. The stock was sold at an average price of $20.96, for a total value of $419,200.00. Following the completion of the sale, the director owned 94,830 shares of the company's stock, valued at $1,987,636.80. This trade represents a 17.42% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 464,621 shares of company stock valued at $9,644,269 in the last ninety days. 3.50% of the stock is currently owned by company insiders.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.